デフォルト表紙
市場調査レポート
商品コード
1373844

ヘモグロビン異常症治療の世界市場 - 市場規模、シェア、成長分析:治療法別、用途別 - 業界予測(2023年~2030年)

Global Hemoglobinopathies Treatment Market Size, Share, Growth Analysis, By Treatment(Stem cell therapy, blood transfusion), By Application(Thalassemia, sick cell anaemia and others) - Industry Forecast 2023-2030

出版日: | 発行: SkyQuest | ページ情報: 英文 157 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
ヘモグロビン異常症治療の世界市場 - 市場規模、シェア、成長分析:治療法別、用途別 - 業界予測(2023年~2030年)
出版日: 2023年10月08日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 目次
概要

世界のヘモグロビン異常症治療の市場規模は、2021年に76億3,000万米ドル、2022年に83億2,000万米ドルとなりました。同市場は、予測期間中(2023年~2030年)に9%のCAGRで拡大し、2030年には165億7,000万米ドルに成長する見通しです。

世界のヘモグロビン異常症治療市場は、鎌状赤血球症(SCD)やサラセミアなどのヘモグロビン異常症の管理・治療を目的とした幅広い治療アプローチやソリューションを包含する急成長分野です。ヘモグロビン異常症は、ヘモグロビンの構造異常や産生異常を特徴とする遺伝性血液疾患群であり、様々な合併症や症状を引き起こします。同市場では、遺伝子治療、幹細胞移植、新規薬物療法など、治療の選択肢が大幅に進歩しています。これらの革新的な治療法は、根本的な遺伝的欠陥に対処し、症状を緩和し、患者の生活の質を改善する可能性を提供します。また、新興国市場では、新規治療法の開発を加速させ、市場に投入するための研究開発活動、共同研究、戦略的提携が急増しています。さらに、これらの疾患に対する意識の高まり、政府の支援策、新興国におけるヘルスケアインフラの改善が、市場の成長を後押ししています。しかし、高額な治療費、特定地域での先進治療へのアクセス制限、専門的な医療従事者の必要性などの課題が、市場拡大の障害となっています。全体として、ヘモグロビン異常症患者のアンメットニーズに対応するため、進行中の研究、技術の進歩、個別化医療アプローチへの重点化の高まりが、世界市場の大幅な成長を後押ししています。

世界のヘモグロビン異常症治療市場の主要促進要因の1つは、個別化医療アプローチへの注目の高まりです。個別化医療は、遺伝的体質、疾患の重症度、治療に対する反応性など、個々の患者の特性に基づいて治療戦略を調整することを目的としています。遺伝子検査や分子診断の進歩により、ヘルスケアプロバイダーはヘモグロビン異常症の根底にある特定の遺伝子変異や異常をよりよく理解できるようになっています。この知識は、治療成績と患者の満足度を向上させる標的療法と精密医療介入の開発を可能にします。個別化医療の重視は、ヘモグロビン異常症の治療効果を高めるだけでなく、革新的な治療オプションの開発も促進します。

世界のヘモグロビン異常症治療市場における主な抑制要因は、先進治療法のコストが高いことです。遺伝子治療や幹細胞移植のような新たな治療法の多くは、複雑な手技、特殊な機器、大規模なフォローアップ医療を伴う。これらの要因は、これらの治療に関連する高コストの一因となっており、患者やヘルスケアシステムにとって経済的負担となっています。特に、医療資源が限られ、低所得者層が多い地域では、先進的な治療法の価格と利用しやすさが課題となっています。高額な治療費は新規治療法の普及を制限し、患者のアクセスを妨げ、ヘモグロビン異常症患者の医療転帰に格差をもたらす可能性があります。すべての患者が効果的な治療を公平に受けられるようにするためには、費用の障壁に対処することが極めて重要です。

当レポートは、世界のヘモグロビン異常症治療市場について調査し、市場の概要とともに、治療法別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

親市場分析

市場規模

  • 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要な市場の洞察

  • 技術分析
  • 価格分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 市場のエコシステム
  • IP分析
  • 動向分析
  • スタートアップ分析
  • 原材料分析
  • イノベーションマトリックス
  • パイプライン製品分析
  • マクロ経済指標
  • トップ投資分析
  • 主な成功要因
  • 競合の程度

市場力学と見通し

  • 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
  • 規制状況
  • ポーター分析

世界のヘモグロビン異常症治療市場、治療法別

  • 市場概要
  • 幹細胞療法
  • 輸血
  • 鉄キレーション療法、その他

世界のヘモグロビン異常症治療市場、用途別

  • 市場概要
  • サラセミア
  • 病細胞性貧血、その他

世界のヘモグロビン異常症治療市場、地域別

  • 市場概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

競合情勢

  • 主要企業プロファイル
    • Sanofi S.A.
    • Global Blood Therapeutics, Inc.
    • bluebird bio, Inc
    • EMI Holding, Inc
    • Celgene Corporation
    • Novartis AG
    • Gilead Sciences, Inc.
    • CRISPR Therapeutics AG
    • Sangamo Therapeutics, Inc.
    • Vertex Pharmaceuticals Incorporated
    • Pfizer Inc.
    • Bioverativ Inc.
    • Acceleron Pharma Inc.
    • Agios Pharmaceuticals, Inc
    • Gamida Cell Ltd.
    • Orchard Therapeutics plc
    • Emmaus Life Sciences, Inc.
    • Pharmacosmos A/S
    • Fresenius SE &Co. KGaA
    • Bluebird R&D Spain SLU
目次
Product Code: SQMIG35H2110

Global Hemoglobinopathies Treatment Market size was valued at USD 7.63 billion in 2021 and is poised to grow from USD 8.32 billion in 2022 to USD 16.57 billion by 2030, at a CAGR of 9% during the forecast period (2023-2030).

The global hemoglobinopathies treatment market is a rapidly growing sector that encompasses a wide range of therapeutic approaches and solutions aimed at managing and treating hemoglobinopathies, including sickle cell disease (SCD) and thalassemia. Hemoglobinopathies are a group of inherited blood disorders characterized by abnormalities in the structure or production of hemoglobin, leading to various complications and symptoms. The market is witnessing significant advancements in treatment options, including gene therapy, stem cell transplantation, and novel drug therapies. These innovative treatments offer the potential to address the underlying genetic defects, alleviate symptoms, and improve the quality of life for patients. The market is also experiencing a surge in research and development activities, collaborations, and strategic partnerships to accelerate the development of novel therapies and bring them to the market. Additionally, increasing awareness about these disorders, supportive government initiatives, and improved healthcare infrastructure in emerging economies are driving market growth. However, challenges such as high treatment costs, limited accessibility to advanced therapies in certain regions, and the need for specialized healthcare professionals pose obstacles to market expansion. Overall, the global market is poised for substantial growth, driven by ongoing research, technological advancements, and a growing emphasis on personalized medicine approaches to address the unmet needs of patients with hemoglobinopathies.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Emergency Lighting Systems Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemoglobinopathies Treatment Market Segmental Analysis

Global Hemoglobinopathies Treatment Market is segmented on the basis of treatment, application and region. By treatment, the market is segmented into Stem cell therapy, blood transfusion, iron chelation therapy and others. By application, the market is segmented into Thalassemia, sick cell anaemia and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Hemoglobinopathies Treatment Market Dynamics

Drivers of the Global Hemoglobinopathies Treatment Market

Increasing focus on personalized medicine approaches

One key driver of the global hemoglobinopathies treatment market is the increasing focus on personalized medicine approaches. Personalized medicine aims to tailor treatment strategies based on individual patient characteristics, including their genetic makeup, disease severity, and response to therapy. With advancements in genetic testing and molecular diagnostics, healthcare providers are able to better understand the specific genetic mutations and abnormalities underlying hemoglobinopathies. This knowledge enables the development of targeted therapies and precision medicine interventions that can improve treatment outcomes and patient satisfaction. The emphasis on personalized medicine not only enhances the effectiveness of hemoglobinopathies treatment but also promotes the development of innovative therapeutic options.

Restraints in the Global Hemoglobinopathies Treatment Market

High cost of advanced therapies

A key restraint of the global hemoglobinopathies treatment market is the high cost of advanced therapies. Many of the emerging treatment modalities, such as gene therapy and stem cell transplantation, involve complex procedures, specialized equipment, and extensive follow-up care. These factors contribute to the high cost associated with these treatments, making them financially burdensome for patients and healthcare systems. The affordability and accessibility of advanced therapies pose challenges, particularly in regions with limited healthcare resources and lower income populations. The high cost of treatment limits the widespread adoption of novel therapies, potentially hindering patient access and leading to disparities in healthcare outcomes for individuals with hemoglobinopathies. Addressing the cost barrier is crucial to ensure equitable access to effective treatments for all patients

Global Hemoglobinopathies Treatment Key Market Trends

Growing emphasis on gene therapy

One key market trend in the global hemoglobinopathies treatment market is the growing emphasis on gene therapy. Gene therapy has emerged as a promising approach for the treatment of hemoglobinopathies, including sickle cell disease and thalassemia. The advancements in genetic engineering techniques, such as CRISPR/Cas9, have provided new possibilities for correcting the genetic mutations underlying these disorders. Gene therapy offers the potential to address the root cause of hemoglobinopathies by introducing functional genes or modifying the existing genes to restore normal hemoglobin production. The increasing research and development activities in gene therapy, along with the successful clinical trials and regulatory approvals, highlight the significant market trend towards this innovative treatment modality.

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
    • Regulatory Landscape
    • Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
  • Global Hemoglobinopathies Treatment Market by Treatment
    • Market Overview
    • Stem cell therapy
    • blood transfusion
    • iron chelation therapy and others
  • Global Hemoglobinopathies Treatment Market by Application
    • Market Overview
    • Thalassemia
    • sick cell anaemia and others
  • Global Hemoglobinopathies Treatment Market Size by Region
    • Market Overview
    • North America
  • USA
  • Canada
    • Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
    • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
    • Latin America
  • Brazil
  • Rest of Latin America
    • Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
  • By Development
  • By Company
  • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Global Blood Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • bluebird bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • EMI Holding, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Celgene Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • CRISPR Therapeutics AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Sangamo Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Vertex Pharmaceuticals Incorporated (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Bioverativ Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Acceleron Pharma Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Agios Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Gamida Cell Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Orchard Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Emmaus Life Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Pharmacosmos A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Bluebird R&D Spain SLU (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments